Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Blood (2018) 132 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2018-99-112669

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Seok Jae Huh, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Won-Sik Lee, Yoojin Lee, MD PhD, Ho Sup Lee, MD

Blood (2018) 132 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2018-99-119473

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Ho-Young Yhim, MD PhD, Yong Park, MD, Joon Ho Moon, MD, Ho-Jin Shin, MD PhD, Yoon Seok Choi, MD, Min Kyoung Kim, MD PhD, Dae Sik Kim, MD PhD, Ji Hyun Lee, MD PhD, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Jun Soo Ham, MD, Seok Jin Kim, MD PhD, Won Seog Kim, MD PhD, Deok-Hwan Yang, MD, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2018-99-115620

Published: 2018

Journal Articles

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Ji Hyun Lee, MD PhD, Sung Yong Oh, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD, Won-Sik Lee, MD, Kwon Kyung A, Yoojin Lee, MD, Ho Sup Lee, MD

Blood (2017) 130 (Supplement 1): 4142.

https://doi.org/10.1182/blood.V130.Suppl_1.4142.4142

Published: 2017

Journal Articles

Effect on Clinical Outcomes of Anemia and Serum Level of Ferritin in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Taeyun Kim, MD, Ho Sup Lee, MD, Jee-Yeong Jeong, PhD, Jae-Cheol Jo, MD PhD, Won-Sik Lee, MD PhD, Ho-Jin Shin, MD, Ji Hyun Lee, MD PhD

Blood (2017) 130 (Supplement 1): 4158.

https://doi.org/10.1182/blood.V130.Suppl_1.4158.4158

Published: 2017

Journal Articles

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity

Chur Woo You, MDPhD, Ho-Jin Shin, MD, Howard Levy, MBBCh, PhD, Martin Lee, PhD, Seung-Beom Hong, PhD, Jamie Ellen Siegel, MD, June Young Park, MD

Blood (2017) 130 (Supplement 1): 87.

https://doi.org/10.1182/blood.V130.Suppl_1.87.87

Published: 2017

Journal Articles

Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy

Ji Hyun Lee, MD PhD, Sung Yong Oh, Ho Sup Lee, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Won-Sik Lee, MD, Kwon Kyung A, Yoojin Lee, MD, Ho-Jin Shin, MD

Blood (2017) 130 (Supplement 1): 2856.

https://doi.org/10.1182/blood.V130.Suppl_1.2856.2856

Published: 2017

Journal Articles

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Blood (2017) 130 (Supplement 1): 3130.

https://doi.org/10.1182/blood.V130.Suppl_1.3130.3130

Published: 2017

Journal Articles

the Effect of Erythropoiesis-Stimulating Agent on the Management of Chemotherapy-Induced Anemia and Tumor Growth in Diffuse Large B-Cell Lymphoma Patients

Lee Chun Park, MD, Ho Sup Lee, MD, Da Jung Kim, MD, Jee-yeong Jeong, PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD, Sung Yong Oh, Young Rok Do, MD PhD

Blood (2017) 130 (Supplement 1): 5209.

https://doi.org/10.1182/blood.V130.Suppl_1.5209.5209

Published: 2017

Journal Articles

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Jae-Ho Yoon, MD PhD, Seok Lee, MD PhD, Dae Sik Kim, MD PhD, Se Ryun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Soo-Mee Bang, MD PhD, Youngil Koh, MD, Ho-Young Yhim, MD, Sang Kyun Sohn, MDPhD, Ik-Chan Song, MD, Hong-ghi Lee, MD PhD, June-Won Cheong, MDPhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD

Blood (2017) 130 (Supplement 1): 5004.

https://doi.org/10.1182/blood.V130.Suppl_1.5004.5004

Published: 2017

Journal Articles

Neutropenia Following Intravenous Immunoglobulin Therapy in Adult Patients with Immune Thrombocytopenic Purpura

Sang Bo Oh, MD, Ho-Jin Shin, MD PhD

Blood (2017) 130 (Supplement 1): 3631.

https://doi.org/10.1182/blood.V130.Suppl_1.3631.3631

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, MBBS, MD, Asher A. Chanan-Khan, MD, Noemi Horvath, FRACP, Marcelo Capra, MD PhD, Roberto Ovilla, MD, Jae-Cheol Jo, MD, Ho-Jin Shin, MD, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, PhD, Pieter Sonneveld, MDPhD, Jordan Schecter, Vania T M Hungria, MD PhD

Blood (2017) 130 (Supplement 1): 1852.

https://doi.org/10.1182/blood.V130.Suppl_1.1852.1852

Published: 2017

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

Blood (2016) 128 (22): 1811.

https://doi.org/10.1182/blood.V128.22.1811.1811

Published: 2016

NARROW

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Effect on Clinical Outcomes of Anemia and Serum Level of Ferritin in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity

Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

the Effect of Erythropoiesis-Stimulating Agent on the Management of Chemotherapy-Induced Anemia and Tumor Growth in Diffuse Large B-Cell Lymphoma Patients

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Neutropenia Following Intravenous Immunoglobulin Therapy in Adult Patients with Immune Thrombocytopenic Purpura

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only